Supporting Information

Aza-aromatic polycycles based on triphenylene and acridine or acridone:

synthesis and properties

Salima Bouarfa,[a,b] Philippe Jéhan,[c] William Erb,[a] Olivier Mongin,[a] François-Hugues Porée,[a]

Thierry Roisnel,[a] Ghenia Bentabed-Ababsa,[b] Nicolas Le Yondre*[c] and Florence Mongin*[c]

New Journal of Chemistry

[a] *Univ Rennes, CNRS, ISCR (Institut des Sciences Chimiques de Rennes) - UMR 6226, F-35000 Rennes, France*

[b] *Laboratoire de Synthèse Organique Appliquée, Faculté des Sciences Exactes et Appliquées, Université d'Oran 1 Ahmed Ben Bella, BP 1524 El M'Naouer, 31000 Oran, Algeria*

[c] *Univ Rennes, CNRS, ScanMat - UMS 2001, Centre Régional de Mesures Physiques de l'Ouest - CRMPO, F-35000, Rennes, France*

E-mails: nicolas.leyondre@univ-rennes1.fr, florence.mongin@univ-rennes1.fr

Table of Contents

General information

Column chromatography separations were achieved on silica gel (40-63 μm). Melting points were measured on a Kofler apparatus. IR spectra were taken on a Perkin-Elmer Spectrum 100 spectrometer. [1]H and [13]C Nuclear Magnetic Resonance (NMR) spectra were recorded either on a Bruker Avance III spectrometer at 300 MHz and 75 MHz respectively, or on a Bruker Avance III HD spectrometer at 500 MHz and 126 MHz respectively. [1]H chemical shifts (δ) are given in ppm relative to the solvent residual peak and ^{13}C chemical shifts are relative to the central peak of the solvent signal.[1] Unless otherwise specified, mass spectra (HRMS) were recorded on an Ultraflex III apparatus in Matrix Assisted Laser Desorption (MALDI) positive mode (Matrix: *trans*-2-[3-(4-*tert*-butylphenyl)-2-methyl-2-propenylidene]malononitrile, DCTB).

Unless otherwise stated, all reagents are commercially available and used as received. After distillation, dimethylsulfoxyde and dimethylformamide were stored on 3Å molecular sieves. Activated copper,[2] 2-iodotriphenylene,[3] 2-aminobenzaldehyde[4] and 9-aminoacridine (9AA)[5] were prepared as reported previously. All reactions involving moisture-sensitive reactants were performed under argon atmosphere. Before use, CDCl$_3$ was neutralized by passing through a short plug of anhydrous, activated basic alumina.

Crystallographic details

The X-ray diffraction data of the compounds **2** and **8** were collected at 150(2) K on a D8 VENTURE Bruker AXS diffractometer equipped with a (CMOS) PHOTON 100 detector by using Mo-Kα radiation (λ = 0.71073 Å, multilayered monochromator). The structures were solved by dual-space algorithm using the *SHELXT* program,[6] and then refined with full-matrix least-square methods based on F^2 (*SHELXL*).[7] All non-hydrogen atoms were refined with anisotropic atomic displacement parameters. H atoms were finally included in their calculated positions and treated as riding on their parent atom with constrained thermal parameters. The molecular diagrams were generated by ORTEP-3 (version 2.02).[8]

Experimental procedures and analyses of the compounds

Synthesis of the compounds 1 and 3 (General procedure).

They were prepared under an argon atmosphere by adapting a procedure reported previously.[9] To a solution of either 2-aminobenzaldehyde[4] (0.12 g, 1.0 mmol), or the commercial 2-aminophenone (1.0 mmol), and 2-iodotriphenylene[3] (0.35 g, 1.0 mmol) in degassed Bu_2O (1 mL) were successively added activated Cu^2 (0.20 equiv, 13 mg, 0.20 mmol) and K_2CO_3 (2 equiv, 0.29 g, 2.0 mmol). The mixture was degassed and refluxed under argon for 12 h. During this time, activated Cu^2 (4 x 13 mg, 4 x 0.2 mmol) was added after 2, 4, 6 and 8 h of heating. After cooling to room temperature, the mixture was concentrated and purified as specified in the product description.

2-(2-Triphenylenyl)aminobenzaldehyde (1). It was prepared according to the general procedure by starting from 2-aminobenzaldehyde.[4] Purification by column chromatography on silica gel (eluent: petroleum ether-AcOEt 90:10; R_f = 0.46) gave **1** in 86% yield (0.31 g) as a yellow solid: mp 182 °C; IR (ATR): 664, 717, 749, 802, 857, 869, 968, 998, 1042, 1052, 1117, 1150, 1185, 1199, 1241, 1319, 1400, 1432, 1452, 1492, 1509, 1581, 1605, 1652, 2751, 2850, 2920, 3053, 3282 cm^{-1}; ^{1}H NMR (CDCl$_3$) δ 6.88-6.93 (m, 1H), 7.44 (d, 2H, J = 3.4 Hz), 7.59-7.71 (m, 6H), 8.52-8.68 (m, 6H), 9.98 (s, 1H, CHO), 10.32 (br s, 1H, NH); ^{13}C NMR (CDCl$_3$) δ 113.2 (CH), 116.5 (CH), 117.6 (CH), 119.8 (C), 122.7 (CH), 123.1 (CH), 123.4 (CH), 123.4 (CH), 123.5 (CH), 124.7 (CH), 126.5 (C), 126.9 (CH), 127.3 (CH), 127.4 (CH), 127.6 (CH), 129.3 (C), 129.4 (C), 129.7 (C), 130.2 (C), 131.1 (C), 135.8 (CH), 136.8 (CH), 138.9 (C), 147.7 (C), 194.4 (CH, CHO).

Phenyl 2-(2-triphenylenyl)aminophenyl ketone (3a). It was prepared according to the general procedure by starting from 2-aminobenzophenone (0.20 g). Purification by column chromatography on silica gel (eluent: petroleum ether-AcOEt 90:10; R_f = 0.50) gave **3a** in 71% yield (0.31 g) as an orange solid: mp 100 °C; IR (ATR): 750, 804, 819, 855, 911, 939, 1001,

1028, 1050, 1075, 1108, 1154, 1246, 1317, 1448, 1490, 1509, 1569, 1599, 2919, 3062, 3277 cm^{-1}; ^{1}H NMR (CDCl$_3$) δ 6.83 (t, 1H, J = 7.5 Hz), 7.44 (td, 1H, J = 7.6 and 1.4 Hz), 7.53-7.64 (m, 9H), 7.70 (dd, 1H, J = 8.0 and 1.3 Hz), 7.89 (d, 2H, J = 6.7 Hz), 8.49-8.59 (m, 6H), 10.55 (s, 1H, NH); ^{13}C NMR (CDCl$_3$) δ 114.8 (CH), 114.9 (CH), 117.0 (CH), 120.2 (C), 121.6 (CH), 122.8 (CH), 123.1 (CH), 123.2 (CH), 123.2 (CH), 124.5 (CH), 125.6 (C), 126.5 (CH), 127.0 (CH), 127.1 (CH), 127.2 (CH), 128.1 (2CH), 129.0 (C), 129.2 (C), 129.5 (2CH), 129.6 (C), 130.0 (C), 130.9 (C), 131.4 (CH), 134.3 (CH), 135.0 (CH), 139.5 (C), 139.7 (C), 147.6 (C), 199.0 (C, C=O).

5-Chloro-2-(2-triphenylenyl)aminophenyl phenyl ketone (3b). It was prepared according to the general procedure by starting from 2-amino-5-chlorobenzophenone (0.23 g) Purification by column chromatography on silica gel (eluent: petroleum ether-AcOEt 90:10; R$_f$ = 0.50) gave **3b** in 91% yield (0.40 g) as an orange powder: mp 160 °C; IR (ATR): 657, 699, 719, 753, 772, 807, 824, 869, 916, 949, 1102, 1118, 1148, 1178, 1236, 1319, 1408, 1444, 1490, 1511, 1571, 1612, 2167, 3057 cm^{-1}; ^{1}H NMR (CDCl$_3$) δ 7.33 (dd, 1H, J = 9.0 and 2.5 Hz, H4), 7.48 (d, 1H, J = 9.1 Hz, H3), 7.51-7.67 (m, 9H), 7.77-7.80 (m, 2H), 8.44 (d, 1H, J = 2.1 Hz, H6), 8.48-8.63 (m, 5H), 10.26 (s, 1H, NH); ^{13}C NMR (CDCl$_3$) δ 115.6 (CH), 116.8 (CH), 121.3 (C), 121.7 (C), 122.1 (CH), 123.1 (CH), 123.4 (CH), 123.5 (CH), 123.5 (CH), 125.0 (CH), 126.3 (C), 126.9 (CH), 127.4 (CH), 127.5 (CH), 127.7 (CH), 128.6 (2CH), 129.4 (C), 129.7 (2CH), 129.8 (C), 130.3 (C), 131.3 (C), 132.1 (CH), 133.90 (CH), 134.3 (CH), 139.1 (C), 139.5 (C), 146.5 (C), 198.2 (C, C=O), 1C not seen.

2-(2-Triphenylenyl)aminoacetophenone (3c). It was prepared according to the general procedure by starting from 2-aminoacetophenone (0.14 g). Purification by column chromatography on silica gel (eluent: petroleum ether-AcOEt 90:10; R$_f$ = 0.475) gave **3c** in 66% yield (0.25 g) as a yellow powder: mp 174 °C; IR (ATR): 657, 700, 717, 751, 770, 807, 869, 949, 1119, 1149, 1177, 1236, 1320, 1408, 1430, 1490, 1513, 1571, 1612, 3057 cm^{-1}; ^{1}H

NMR (CDCl$_3$) δ 2.70 (s, 3H, Me), 6.81 (ddd, 1H, J = 8.1, 6.9 and 1.2 Hz), 7.37 (ddd, 1H, J = 8.5, 6.9 and 1.5 Hz), 7.46 (dd, 1H, J = 8.5 and 1.0 Hz), 7.57 (dd, 1H, J = 8.8 and 2.2 Hz), 7.60-7.69 (m, 4H), 7.88 (dd, 1H, J = 8.1 and 1.4 Hz), 8.48 (d, 1H, J = 2.2 Hz), 8.52-8.66 (m, 5H), 10.85 (s, 1H, NH); ^{13}C NMR (CDCl$_3$) δ 28.3 (CH$_3$), 114.6 (CH), 116.4 (CH), 117.1 (CH), 119.6 (C), 122.8 (CH), 123.1 (CH), 123.4 (CH), 123.5 (CH), 123.5 (CH), 124.7 (CH), 126.2 (C), 126.8 (CH), 127.3 (CH), 127.4 (CH), 127.5 (CH), 129.4 (C), 129.5 (C), 129.8 (C), 130.2 (C), 131.1 (C), 132.7 (CH), 134.8 (CH), 139.7 (C), 147.8 (C), 201.5 (C, C=O).

Ethyl 2-(2-triphenylenyl)aminobenzoate (5). It was prepared under an argon atmosphere by adapting a procedure reported previously.[9] To commercial ethyl anthranilate (ethyl 2-aminobenzoate; 0.17 g, 1.0 mmol) and 2-iodotriphenylene[3] (0.35 g, 1.0 mmol) in degassed Bu$_2$O (1 mL) were successively added activated Cu^2 (0.20 equiv, 13 mg, 0.20 mmol) and K$_2$CO$_3$ (2 equiv, 0.29 g, 2.0 mmol). The mixture was degassed and refluxed under argon for 12 h. During this time, activated Cu^2 (4 x 13 mg, 4 x 0.2 mmol) was added after 2, 4, 6 and 8 h of heating. After cooling to room temperature, the mixture was concentrated. Purification by column chromatography on silica gel (eluent: petroleum ether-AcOEt 98:2; R$_f$ = 0.575) gave **5** in 88% yield (0.34 g) as a yellow solid: mp 135 °C; IR (ATR): 700, 718, 749, 813, 857, 872, 944, 1025, 1050, 1083, 1148, 1162, 1235, 1246, 1316, 1368, 1395, 1442, 1453, 1491, 1513, 1581, 1602, 1617, 1671, 2979, 3313 cm-1; ^{1}H NMR (CDCl$_3$) δ 1.47 (t, 3H, J = 7.1 Hz), 4.44 (q, 2H, J = 7.1 Hz), 6.84 (t, 1H, J = 7.5 Hz), 7.40 (td, 1H, J = 7.8 and 1.4 Hz), 7.49 (d, 1H, J = 8.4 Hz), 7.56 (dd, 1H, J = 8.8 and 2.1 Hz), 7.59-7.67 (m, 4H), 8.09 (dd, 1H, J = 8.0 and 1.3 Hz), 8.45-8.64 (m, 6H), 9.87 (br s, 1H, NH); ^{13}C NMR (CDCl$_3$) δ 14.5 (CH$_3$), 60.9 (CH$_2$), 112.8 (C), 114.4 (CH), 115.4 (CH), 117.6 (CH), 122.1 (CH), 123.0 (CH), 123.3 (CH), 123.4 (CH), 123.4 (CH), 124.6 (CH), 125.7 (C), 126.6 (CH), 127.2 (CH), 127.3 (CH), 127.4 (CH), 129.2 (C), 129.4 (C), 129.8 (C), 130.2 (C), 131.1 (C), 131.9 (CH), 134.2 (CH), 140.1 (C), 147.7 (C), 168.7 (C).

2-(2-Triphenylenyl)aminobenzoic acid (6) was prepared by adapting a procedure reported previously.[10] Ethyl 2-(2-triphenylenyl)aminobenzoate (**5**; 0.39 g, 1.0 mmol) was suspended in acetone (10 mL) and treated by 10 mL of a 5% aqueous solution of sodium hydroxide (12 mmol). The reaction mixture was refluxed for 16 h and cooled to room temperature. The solvent was removed under reduced pressure. CH_2Cl_2 (30 mL) and water (20 mL) were added to the residue. The aqueous phase was collected and acidified until pH = 1 by addition at 0 °C of concentrated hydrochloric acid. The obtained precipitate was dried under vacuum at 100 °C for 2 h and used in the next step without further purification. Compound **6** was obtained in a quantitative yield (0.36 g) as a beige solid: mp > 260 °C; IR (ATR): 719, 745, 760, 882, 919, 1043, 1162, 1252, 1319, 1338, 1434, 1450, 1491, 1509, 1570, 1617, 1664, 2567, 2839, 3342 cm-1; ^{1}H NMR ((CD_3)$_2$SO) δ 6.85-6.90 (m, 1H), 7.47 (d, 2H, J = 3.7 Hz), 7.62-7.74 (m, 5H), 7.98 (d, 1H, J = 8.2 Hz), 8.59 (d, 1H, J = 1.8 Hz, H1'), 8.71-8.81 (m, 5H), 9.96 (br s, 1H, NH), 13.17 (br s, 1H, CO_2H); ^{13}C NMR ((CD_3)$_2$SO) δ 113.5 (C), 114.2 (CH), 114.4 (CH), 118.0 (CH), 121.2 (CH), 123.1 (CH), 123.5 (CH), 123.5 (CH), 123.7 (CH), 124.6 (C), 125.0 (CH), 126.8 (CH), 127.5 (CH), 127.6 (CH), 127.7 (CH), 128.4 (C), 128.8 (C), 129.2 (C), 129.5 (C), 130.5 (C), 131.9 (CH), 134.2 (CH), 140.3 (C), 146.4 (C), 169.8 (C, C=O).

NMR spectra

2-(2-Triphenylenyl)aminobenzaldehyde (1)

^{1}H NMR (300 MHz, CDCl$_3$)

^{13}C NMR (75 MHz, CDCl$_3$)

Phenanthro[9,10-*a*]acridine (2)

^{1}H NMR (500 MHz, CDCl$_3$)


^{13}C NMR (75 MHz, CDCl$_3$)

COSY (500 MHz, CDCl₃)


HSQC (500 MHz, CDCl₃)

NOESY (500 MHz, CDCl₃)

Phenyl 2-(2-triphenylenyl)aminophenyl ketone (3a)

^{1}H NMR (300 MHz, CDCl$_3$)


^{13}C NMR (75 MHz, CDCl$_3$)

5-Chloro-2-(2-triphenylenyl)aminophenyl phenyl ketone (3b)

^{1}H NMR (300 MHz, CDCl$_3$)

sbouarfa BS126-pd

10.2570

8.6745
8.5291
8.4974
8.4902
7.7891
7.7573
7.7011
7.5367
7.5237
7.4936
7.3674
7.3590
7.3372
7.3288

8.6338
8.4844
8.4442
8.4371

7.8032
7.7714
7.6750
7.5059
7.4945
7.4641
7.3452
7.3369
7.3151
7.3067

4.92
1.00
1.96
10.04
1.03

1.00
5.00
0.96
2.01
10.10
0.98

f1 (ppm)

^{13}C NMR (75 MHz, CDCl$_3$)

sbouarfa BS126-pd

198.1922

146.5250
139.4875
139.1192
134.3492
133.8984
132.1376
131.2684
130.3348
129.7988
129.6565
129.4019
128.5784
127.6760
127.5028
127.3899
126.9485
126.2649
124.9701
123.5464
123.4928
123.4691
123.1226
122.0618
121.7473
121.3109
116.7577
115.5709

f1 (ppm)

S12

2-(2-Triphenylenyl)aminoacetophenone (3c)

^{1}H NMR (300 MHz, CDCl$_3$)

^{13}C NMR (75 MHz, CDCl$_3$)

15-Phenylphenanthro[9,10-*b*]acridine (4a)

¹H NMR (300 MHz, CDCl₃)

^{1}H NMR (300 MHz, CDCl$_3$)

## ¹³C NMR (75 MHz, CDCl₃)

^{13}C NMR (75 MHz, CDCl$_3$)

13-Chloro-15-phenylphenanthro[9,10-*b*]acridine (4b)

¹H NMR (500 MHz, CDCl₃)

¹³C NMR (75 MHz, CDCl₃)

NOESY (500 MHz, CDCl₃)

15-Methylphenanthro[9,10-*b*]acridine (4c)

¹H NMR (500 MHz, CDCl₃) – lower concentration (about 1 mg in 0.5 mL)

¹H NMR (500 MHz, CDCl₃) – higher concentration (about 2 mg in 0.5 mL)

S17

^{13}C NMR (126 MHz, CDCl$_3$)

werb BS-127-Cyc-ine-ana

132.4376
130.6180
130.3694
130.1629
130.0301
129.7817
128.6968
128.2544
128.2071
127.9916
127.7793
125.5409
125.3322
124.7685
124.5772
124.4731
123.8116
123.6847
123.4893
118.6439

13.9968

werb BS-127-Cyc-ine-ana

132.4376

130.6180
130.3694
130.1629
130.0301
129.7817

128.6968
128.2544
128.2071
127.9916
127.7793

125.5409
125.3322
124.7685
124.5772
124.4731
123.8116
123.6847
123.4893

118.6439

S18

Ethyl 2-(2-triphenylenyl)aminobenzoate (5)

^{1}H NMR (300 MHz, CDCl$_3$)

¹³C NMR (75 MHz, CDCl₃)

^{13}C NMR (75 MHz, CDCl$_3$)

sbouarfa BS136 Pd

168.7319
147.7955
140.1874
134.2640
131.9019
131.1795
130.2673
129.9172
129.5226
129.2848
127.4933
127.4113
127.2799
126.7276
125.8401
124.7319
123.4722
123.4387
123.0498
122.2281
117.6913
115.4749
114.4312
112.8691
60.9077
14.5100

f1 (ppm)

2-(2-Triphenylenyl)aminobenzoic acid (6)

^{1}H NMR (300 MHz, (CD$_3$)$_2$SO)


^{13}C NMR (75 MHz, (CD$_3$)$_2$SO)

16-Chlorophenanthro[9,10-*a*]acridine (7)

## ^{1}H NMR (300 MHz, CDCl$_3$)

^{13}C NMR (75 MHz, CDCl$_3$)

16-Phenoxyphenanthro[9,10-*a*]acridine (8)

^{1}H NMR (300 MHz, CDCl$_3$)

^{13}C NMR (75 MHz, CDCl$_3$)

16-(4-Aminophenoxy)phenanthro[9,10-*a*]acridine (9)

¹H NMR (400 MHz, CDCl₃)

¹H NMR (400 MHz, CDCl₃)

^{13}C NMR (101 MHz, CDCl$_3$)

werb BS-147-F3-ana-bis

156.6228
151.4901
150.3589
149.7155
140.8470
131.3589
129.2804
129.0213
127.3785
126.4323
125.4752
123.7215
116.3853
115.3931
114.8056

f1 (ppm)

N,N-Bis(2-triphenylenyl)-2-aminobenzaldehyde (10)

¹H NMR (500 MHz, CDCl₃)

¹³C NMR (125 MHz, CDCl₃)

N-(2-Triphenylenyl)phenanthro[9,10-*b*]-15-acridone (11)

¹H NMR (500 MHz, CDCl₃) – lower concentration (about 0.5 mg in 0.5 mL)

¹H NMR (500 MHz, CDCl₃) – lower concentration (about 0.5 mg in 0.5 mL)

^{13}C NMR (126 MHz, CDCl$_3$)

werb BS-112-F3-Cyc-Yb-ana

178.7873
133.9016
129.2612
128.7203
128.5058
128.4804
128.0151
127.9752
127.8947
127.7666
127.4524
126.9874
124.1362
124.0064
123.8970
123.8284
123.7095
123.5904
123.3685
123.3049
121.7155
121.6553
116.2115
116.9875

f1 (ppm)

N-Phenyl-*N*-(2-triphenylenyl)-2-aminobenzaldehyde (12)

^{1}H NMR (500 MHz, CDCl$_3$)

^{13}C NMR (126 MHz, CDCl$_3$)

N-(2-Triphenylenyl)-9-acridone (13)

^{1}H NMR (500 MHz, CDCl$_3$)

^{13}C NMR (126 MHz, CDCl$_3$)

NOESY (500 MHz, CDCl₃)

Highest occupied Hückel molecular orbitals (HOMO)

A

$\varepsilon = \alpha + 0{,}51\beta$

B

$\varepsilon = \alpha + 0{,}46\beta$

C

$\varepsilon = \alpha + 0{,}42\beta$

1

$\varepsilon = \alpha + 0{,}49\beta$

3a

$\varepsilon = \alpha + 0{,}49\beta$

3b

$\varepsilon = \alpha + 0{,}48\beta$

3c

ε = α + 0,49β

5

ε = α + 0,49β

10

$\epsilon = \alpha + 0,41\beta$

12

$\epsilon = \alpha + 0,43\beta$

Qualitative evaluation of 8 and 9 as matrices for MALDI-MS

Matrices

DCTB, HCCA, 9-AA, **8** and **9** were used as matrices.

Name	Structure	Formula	$[M-H]^-$	$[M+H]^+$	$[M+Na]^+$
DCTB		$C_{17}H_{18}N_2$	249.14	251.15	273.14
HCCA		$C_{10}H_7NO_3$	188.04	190.05	212.03
9-AA		$C_{13}H_{10}N_2$	193.08	195.09	217.07
8		$C_{31}H_{19}NO$	420.14	422.15	444.14
9		$C_{31}H_{20}N_2O$	435.15	437.16	459.15

Target compounds

#	Dénomination	Formula	$[M-H]^-/A^-$	$[M+H]^+$	$[M+Na]^+$	$[M+K]^+$	$[M-H+2Na]^+$
1	Aspirin	$C_9H_8O_4$	179.03	181.05	203.03	219.01	225.01
2	Captopril	$C_9H_{15}NO_3S$	216.07	218.08	240.07	256.05	262.05
3	Metolachlor ESA	$C_{15}H_{23}NO_5S$	328.12	330.14	352.12	368.09	374.10
4	Paracetamol	$C_8H_9NO_2$	150.06	152.07	174.05	190.03	196.03
5	Phenytoin	$C_{15}H_{12}N_2O_2$	251.08	253.10	275.08	291.05	297.06
6	Penicilin V	$C_{16}H_{18}N_2O_5S$	349.09	351.10	373.08	389.06	395.06
7	Penicillin V (K)	(A^-: $C_{16}H_{17}N_2O_5S$; K^+)	349.09	389.06	411.04	427.01	433.02
8	SDS	(A^-: $C_{12}H_{25}O_4S$;Na^+)	265.15	289.14	311.13	327.10	333.11
9	Sodium taurocholate	(A^-: $C_{26}H_{44}NO_7S$;Na^+)	514.28	538.28	560.26	576.24	582.24

<u>Qualitative detection</u>

The experiments were performed in both positive and negative modes, with five matrices (DCTB, HCCA, 9-AA, **8** and **9**), with two solvents for a two-layer spotting (90 spots and 180 experiments).

Matrices were dissolved at 10 mg/mL in methanol or dichloromethane. Target compounds were dissolved at 1 mg/mL in the same solvent. The solutions were dispensed onto an MTP AnchorChip 384 TF target (Bruker Daltonics, P/N 209514) with a GELoader pipette tip. A first layer of target compounds mixture was twice spotted (2*0.25 µL) and dried at room temperature. A second layer of matrix mixture was twice spotted (2*0.25 µL) and dried at room temperature. The 90 spots were analyzed with an Ultraflex III MALDI-TOF/TOF mass spectrometer (Bruker Daltonics) operating under Flex Control™ software (Version 3.4, Build 119, Bruker Daltonics). MALDI-TOF spectra were observed in positive and negative ion reflector mode recording ions between 100 to 2000 Da. The laser power was adjusted to a point slightly above the fluence of the base peak and fired to accumulate 500 counts on the base peak with 200 laser shots. Analysis and annotations of MS spectra were performed manually.

Qualitative information and evaluation factors

For the qualitative information, evaluation factors were chosen and scaled from 0 to 6.

Laser power is better with a small value.

Laser Power	<15%	15-24%	25-34%	35-44%	45-55%	56-65%	>66%
Laser (+ or -)	6	5	4	3	2	1	0

The presence of the target compounds is represented by the factor target.in in correlation with the relative intensity in mass spectrum.

Relative Intensity	Base peak (100%)	Intense (50-99%)	Present (10-49%)	Weak (1-10%)	Traces (1%)	Not seen
Target.in (+ or -)	5	4	3	2	1	0

A factor [Product.LT] representing both the laser power applied and the presence of target compounds was calculated by summing the multiplications of Target.in(+) by Laser(+) and Target.in(-) by Laser(-).

The number of target compounds obtained as a base peak, in positive, negative or in both, without redundancy is specified with the factor Target.BP:

	Target.BP(-)	Target.BP(+)	Target.BP
DCTB	3	3	5
HCCA	0	1	1
9-AA	3	0	3
8	3	1	3
9	3	0	3

Experiments overview tables

For the matrix DCTB

#+	#-	Product	Matrix	Solvent	Laser(+)	Laser(-)	Target.in(+)	Target.in(-)	Product.LT
1	91	1	DCTB	CH_2Cl_2	5	5	0	0	0
6	96	1	DCTB	MeOH	5	5	0	0	0
11	101	2	DCTB	CH_2Cl_2	6	5	3	1	23
16	106	2	DCTB	MeOH	5	5	0	2	10
21	111	3	DCTB	CH_2Cl_2	5	4	5	5	45
26	116	3	DCTB	MeOH	5	5	4	5	45
31	121	4	DCTB	CH_2Cl_2	6	4	2	0	12
36	126	4	DCTB	MeOH	5	4	4	0	20
41	131	5	DCTB	CH_2Cl_2	6	4	3	1	22
46	136	5	DCTB	MeOH	5	4	0	0	0
51	141	6	DCTB	CH_2Cl_2	5	4	5	0	25
56	146	6	DCTB	MeOH	5	4	4	0	20
61	151	7	DCTB	CH_2Cl_2	5	5	5	2	35
66	156	7	DCTB	MeOH	5	5	4	2	30
71	161	8	DCTB	CH_2Cl_2	6	5	0	5	25
76	166	8	DCTB	MeOH	5	5	1	5	30
81	171	9	DCTB	CH_2Cl_2	5	5	0	2	10
86	176	9	DCTB	MeOH	5	5	0	5	25
				Average values	5,22	4,61	2,22	1,94	20,94

For the matrix HCCA

#+	#-	Product	Matrix	Solvent	Laser(+)	Laser(-)	Target.in(+)	Target.in(-)	Product.LT
2	92	1	HCCA	CH_2Cl_2	3	2	0	0	0
7	97	1	HCCA	MeOH	3	4	0	0	0
12	102	2	HCCA	CH_2Cl_2	3	3	4	0	12
17	107	2	HCCA	MeOH	5	4	3	0	15
22	112	3	HCCA	CH_2Cl_2	2	0	2	0	4
27	117	3	HCCA	MeOH	4	5	2	1	13
32	122	4	HCCA	CH_2Cl_2	5	1	2	0	10
37	127	4	HCCA	MeOH	5	4	1	0	5
42	132	5	HCCA	CH_2Cl_2	3	1	0	0	0
47	137	5	HCCA	MeOH	5	4	0	0	0
52	142	6	HCCA	CH_2Cl_2	4	2	0	0	0
57	147	6	HCCA	MeOH	5	3	5	0	25
62	152	7	HCCA	CH_2Cl_2	4	0	0	0	0
67	157	7	HCCA	MeOH	4	4	0	0	0
72	162	8	HCCA	CH_2Cl_2	2	0	0	0	0
77	167	8	HCCA	MeOH	5	3	2	4	22
82	172	9	HCCA	CH_2Cl_2	5	4	0	0	0
87	177	9	HCCA	MeOH	5	4	0	2	8
				Average values	4,00	2,67	1,17	0,39	6,33

For the matrix 9-AA

#+	#-	Product	Matrix	Solvent	Laser(+)	Laser(-)	Target.in(+)	Target.in(-)	Product.LT
3	93	1	9-AA	CH_2Cl_2	3	3	0	1	3
8	98	1	9-AA	MeOH	3	2	0	1	2
13	103	2	9-AA	CH_2Cl_2	4	1	0	0	0
18	108	2	9-AA	MeOH	3	2	0	2	4
23	113	3	9-AA	CH_2Cl_2	4	3	2	5	23
28	118	3	9-AA	MeOH	3	2	1	5	13
33	123	4	9-AA	CH_2Cl_2	3	1	0	1	1
38	128	4	9-AA	MeOH	4	1	0	0	0
43	133	5	9-AA	CH_2Cl_2	3	2	0	4	8
48	138	5	9-AA	MeOH	3	2	0	2	4
53	143	6	9-AA	CH_2Cl_2	3	1	0	0	0
58	148	6	9-AA	MeOH	2	1	0	0	0
63	153	7	9-AA	CH_2Cl_2	3	2	0	0	0
68	158	7	9-AA	MeOH	3	2	3	0	9
73	163	8	9-AA	CH_2Cl_2	4	1	0	2	2
78	168	8	9-AA	MeOH	4	1	0	5	5
83	173	9	9-AA	CH_2Cl_2	4	2	0	5	10
88	178	9	9-AA	MeOH	4	3	0	5	15
				Average values	3,33	1,78	0,33	2,11	5,50

For the matrix **8**

#+	#-	Product	Matrix	Solvent	Laser(+)	Laser(-)	Target.in(+)	Target.in(-)	Product.LT
4	94	1	**8**	CH_2Cl_2	4	2	0	0	0
9	99	1	**8**	MeOH	3	2	0	0	0
14	104	2	**8**	CH_2Cl_2	2	2	0	0	0
19	109	2	**8**	MeOH	3	3	0	0	0
24	114	3	**8**	CH_2Cl_2	3	1	5	3	18
29	119	3	**8**	MeOH	3	2	1	5	13
34	124	4	**8**	CH_2Cl_2	3	1	0	0	0
39	129	4	**8**	MeOH	4	2	0	0	0
44	134	5	**8**	CH_2Cl_2	3	3	0	4	12
49	139	5	**8**	MeOH	3	2	0	2	4
54	144	6	**8**	CH_2Cl_2	3	2	0	0	0
59	149	6	**8**	MeOH	3	1	0	0	0
64	154	7	**8**	CH_2Cl_2	3	2	0	0	0
69	159	7	**8**	MeOH	3	1	0	0	0
74	164	8	**8**	CH_2Cl_2	4	1	0	5	5
79	169	8	**8**	MeOH	3	1	0	4	4
84	174	9	**8**	CH_2Cl_2	3	2	0	5	10
89	179	9	**8**	MeOH	3	2	0	4	8
				Average values	3,11	1,78	0,33	1,78	4,11

For the matrix **9**

| #+	#-	Product	Matrix	Solvent	Laser(+)	Laser(-)	Target.in(+)	Target.in(-)	Product.LT
5	95	1	**9**	CH_2Cl_2	3	3	0	1	3
10	100	1	**9**	MeOH	3	1	0	1	1
15	105	2	**9**	CH_2Cl_2	3	2	0	0	0
20	110	2	**9**	MeOH	3	3	0	0	0
25	115	3	**9**	CH_2Cl_2	3	2	4	5	22
30	120	3	**9**	MeOH	3	2	4	5	22
35	125	4	**9**	CH_2Cl_2	3	2	0	0	0
40	130	4	**9**	MeOH	4	2	0	0	0
45	135	5	**9**	CH_2Cl_2	3	2	0	0	0
50	140	5	**9**	MeOH	3	2	0	2	4
55	145	6	**9**	CH_2Cl_2	3	2	0	0	0
60	150	6	**9**	MeOH	3	1	0	0	0
65	155	7	**9**	CH_2Cl_2	3	2	0	0	0
70	160	7	**9**	MeOH	3	2	0	0	0
75	165	8	**9**	CH_2Cl_2	4	1	0	0	0
80	170	8	**9**	MeOH	3	3	0	5	15
85	175	9	**9**	CH_2Cl_2	4	3	0	5	15
90	180	9	**9**	MeOH	3	4	0	5	20
				Average values	3,17	2,17	0,44	1,61	5,67

The average values as a percentage are summarized in order to generate the Kiviat's diagram.

|	Product.LT	Laser(+)	Target.in(+)	Target.BP(+)	Target.BP	Target.BP(-)	Target.in(-)
DCTB	34,9	87,0	44,4	33,3	55,6	33,3	38,8
HCCA	10,6	66,7	23,2	11,1	11,1	0,0	7,8
9-AA	9,2	55,5	6,6	0,0	33,3	33,3	42,2
8	6,9	51,8	6,6	11,1	33,3	33,3	35,6
9	9,5	52,8	8,8	0,0	33,3	33,3	32,2

Qualitative analysis of the five matrices

## Qualitative analysis of DCTB *vs.* HCCA

Qualitative analysis of DCTB *vs.* 9-AA

Qualitative analysis of 9-AA, **8** and **9**

References and Notes

1. Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. *J. Org. Chem.* **1997**, *62*, 7512-7515.
2. Vogel, A. I.; Tatchell, A. R.; Furnis, B. S.; Hannaford, A. J.; Smith, P. W. G. *Vogel's textbook of practical organic chemistry, 5th edn, Prentice Hall*, 1996.
3. Nandy, R.; Sankararaman, S. *Org. Biomol. Chem.* **2010**, *8*, 2260-2266.
4. Zhang, C.; De, C. K.; Seidel, D. *Org. Synth.* **2012**, *89*, 274-282.
5. Borovlev, I. V.; Demidov, O. P.; Amangasieva, G. A.; Avakyan, E. K. *Tetrahedron Lett.* **2016**, *57*, 3608-3611.
6. Sheldrick, G. M. *Acta Crystallogr., Sect. A* **2015**, *71*, 3-8.
7. Sheldrick, G. M. *Acta Crystallogr., Sect. C* **2015**, *71*, 3-8.
8. Farrugia, L. J. *J. Appl. Crystallogr.* **1997**, *30*, 565.
9. Bouarfa, S.; Bentabed-Ababsa, G.; Erb, W.; Picot, L.; Thiery, V.; Roisnel, T.; Dorcet, V.; Mongin, F. *Synthesis* **2021**, *53*, 1271-1284.
10. Bertrand, H.; Guillot, R.; Teulade-Fichou, M.-P.; Fichou, D. *Chem. Eur. J.* **2013**, *19*, 14654-14664.